Results 151 to 160 of about 1,042 (183)

Chemotherapy of schistosomal colonic polyposis with oxamniquine

Transactions of the Royal Society of Tropical Medicine and Hygiene, 1978
Schistosomal polyposis of the colon is a common complication of schistosomiasis. In severe infections it may be associated with considerable morbidity. Surgery is associated with high morbidity and mortality. Niridazole therapy is of limited therapeutic value because of its hepatotoxicity but oxaminiquine has been found to be effective and safe ...
H H, Abaza, N, Hammouda, H A, Rabbo, A Z, Shafei   +3 more
openaire   +2 more sources

Preliminary Investigations of Some Derivatives of Oxamniquine

Journal of Chemotherapy, 1995
Oxamniquine is a potent schistosomicide used clinically in the treatment of infections due to Schistosoma mansoni. Although relatively well tolerated, some central nervous system (CNS) effects characterised by convulsions have been reported in a small proportion of the population receiving this drug.
C W, Karekezi, P D, Lucas, B A, Marples, W G, Salt   +3 more
openaire   +2 more sources

Pharmacokinetics of oxamniquine in rabbit and rat

European Journal of Drug Metabolism and Pharmacokinetics, 1996
The pharmacokinetics of the schistosomicidal agent oxamniquine (6-hydroxmethyl-2-isopropylaminomethyl-7-nitro-1,2,3,4-tetra hydroquinoline) were studied in 8 (4 male, 4 female) New Zealand White rabbits and 5 female Wistar rats, following intravenous administration (15 mg/kg).
Kokwaro, GO, Indalo, Anne A, Taylor, G
openaire   +2 more sources

Synthesis and evaluation of new oxamniquine derivatives

International Journal of Pharmaceutics, 2002
Oxamniquine derivatives were synthesized and evaluated as novel schistosomicide agents. Oxamniquine (1,2,3,4-tetrahydro-2-[[(1-methylethyl)amino]methyl]-7-nitro-6-quinolinemethanol) was submitted to the Mannich reaction, using formaldehyde, paraformaldehyde and acetaldehyde as reagents, and gave three unexpected products: two of them were cyclized on ...
Silvio Barberato, Filho, Cybele, Gargioni, Pedro Luiz, Silva Pinto, Silvia Gabriel, Chiodelli, Sylvia Amaral, Gurgel Vellosa, Rita Maria, da Silva, Maria Amélia Barata, da Silveira   +6 more
openaire   +2 more sources

Determination of oxamniquine in capsules by HPLC

Journal of Pharmaceutical and Biomedical Analysis, 2001
A sensitive, accurate, reliable and easy method was developed for the quantification of oxamniquine in capsules using high-performance liquid chromatography (HPLC) with UV detection. This technique provided conditions for the separation of the active ingredient from the dosage form by extraction in methanol.
Pierri, E. G., Almeida, Adelia Emilia de, Gremiao, MPD   +2 more
openaire   +3 more sources

Binding of oxamniquine to the DNA of schistosomes

Transactions of the Royal Society of Tropical Medicine and Hygiene, 1989
Hycanthone-sensitive and hycanthone-resistant schistosomes (which are also sensitive and resistant to oxamniquine) were exposed in vitro to tritium-labelled oxamniquine. The initial uptake of the drug into the schistosomes was essentially the same for the 2 strains.
L, Pica-Mattoccia, D, Cioli, S, Archer
openaire   +2 more sources

Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine

Bioorganic & Medicinal Chemistry, 2017
Neglected tropical diseases (NTDs) are a group of diseases that, besides prevailing in poverty conditions, contribute to the maintenance of social inequality, being a strong barrier to a country development. Schistosomiasis, a NTD, is a tropical and subtropical disease caused by the trematode Schistosoma mansoni (Africa, Middle East, Caribbean, Brazil,
Vinícius Barros Ribeiro da Silva, Bruna Rafaella Koresch Leiva Campos, Jamerson Ferreira de Oliveira, Jean-Luc Decout, Maria do Carmo Alves de Lima   +4 more
openaire   +2 more sources

The metabolism of oxamniquine in the gut wall

Xenobiotica, 1980
1. The extent of metabolism of oxamniquine, 6-hydroxymethyl-7-nitro-2-isopropylaminomethyl-1,2,3,4-tetrahydroquinoline, in the gut of the dog has been studied using an intestinal preparation which allows collection of the outflow from the portal vein. 2.
B, Kaye, D W, Roberts
openaire   +2 more sources

Oxamniquine pharmacokinetics in hepatosplenic schistosomiasis in the Sudan

Journal of Antimicrobial Chemotherapy, 1987
Oxamniquine pharmacokinetics were determined in five normal Sudanese subjects and nine Sudanese patients with advanced hepatosplenic schistosomiasis, given 1 g as a single oral dose. There were no significant differences in oxamniquine mean area under the plasma concentration time curve (AUC), plasma half life (T1/2), or time to reach peak ...
T K, Daneshmend, M A, Homeida
openaire   +2 more sources

A review of clinical experience with oxamniquine

Transactions of the Royal Society of Tropical Medicine and Hygiene, 1987
Oxamniquine has now been in general use for 11 years for the treatment of schistosomiasis mansoni. Dosage varies with the geographical origin of the parasites due to different susceptibilities of local strains, and the appropriate regimen can be expected to cure over 80% of patients and reduce egg excretion in others by over 90%. The drug has been used
openaire   +2 more sources